Personalized Medicine Universe, Volume: 4, Pages: 32-39. 2015
Mycoplasma Infectious Diseases (MID) are systemic illnesses that cause vasculitis and neuritis. MID not only includes pneumonia but also diseases such as asthma, arthritis, nephritis, meningitis, encephalitis, dermatitis, pancreatitis, hepatitis, and hematologic illnesses. Regrettably, conventional diagnosis has. Regrettably, conventional diagnosis has. Therefore, it is often confusing and difficult to identify Mycoplasma-infected patients among those with incurable diseases, such as autoimmune diseases, rheumatic diseases, nervous system disorders, and hematological disorders. Only been available for pneumonia, although it is critical to identify MID at early stages for effective medical treatment. A cutting-edge technology has made it possible to measure the amount of specific antibodies to species-specific mycoplasma glycolipid-antigens. This new technology provides a reliable marker to follow the state of MID by monitoring antibody titer fluctuations. A novel therapeutic strategy based on new serological diagnostics is introduced in this review.
Volume: 38, Pages: 34. Mar 31, 2012
This is your Service Description. Use this space to explain this service in more detail.
Molecular mechanisms of lipid-antigen recognition are important in the frontier of immunology. Possible pathogeneses of autoimmune diseases and tumours now include infections with microorganisms. Therefore, the role of vaccines is increasingly important, as advancing technology has now broadened the targets of vaccination to include To prevent infectious diseases through vaccination, it is important to identify specific antigens, which often exists in the cell membrane and capsule and also become the center of host–pathogen. Structural analysis of lipid-antigens is critical for understanding the mechanisms of molecular interactions involved in the pathogens is of immune abnormalities, and for devising strategies surrounding immune system regulation and drug discovery.
Akira Miyachi, Atsushi Miyazaki, Yuko Shingu, Kazuhiro Matsuda, Hirofumi Dohi, Yoshihiro Nishida
Carbohydrate research, Issue: 1, Volume: 344, Pages: 36-43. Nov 1, 2008
They are the major immunodeterminants of this pathogenic Mycoplasma and indicate high medicinal potential. They have a beta-(1-- > 6)-linked disaccharide structure close to each other; one has beta-d-galactopyranoside (beta-Gal-type 1) at the non-reducing terminal, and another has beta-d-glucopyranoside (beta-Glc-type 2) In the present study, the first stereoselective synthesis was conducted for each of the two beta-glycolipids 1 and 2. (1) H NMR and TLC-immunostaining studies of the synthetic compounds enable us to establish the absolute structures having the beta-(1) 1-> 6)-linked disaccharides at the glycerol sn-3 position.
Kazuo Fukuda, Kazuhiro Matsuda, Sachie Matsuda, Sayaka Kado, Hyuma Masu, Hirofumi Dohi, Yoshihiro Nishida
Bioorganic & medicinal chemistry, Issue: 4, Volume: 26, Pages: 824-832. Dec 28, 2017
Abstract Mycoplasma pneumoniae expresses β-glycolipids (β-GGLs) in cytoplasmic membranes, which possess a unique β (1-> 6)-linked disaccharide epitope, which has high potential in biochemical and medicinal applications. In the present study, a series An ELISA assay using an anti-(β-GGLs) monoclonal antibody indicated that the synthetic homologues with long acyl chains had greater diagnostic potential in the order C18> C16> C14> C12. Toward a simultaneous detection of natural glycolipids by mass spectrometry (MS), a deuterium-labeled C16 homologue (β-GGL-C16-d3) was prepared and applied as an internal standard for a high-resolution electrospray ionization MS (ESI-MS) analysis. The ESI-MS analysis was used to identify and quantify acyl homologues (C16 / C16, C16 / C18, and C18 / C18) of β-GGL-C16 in cultured M. pneumoniae. A β-GGLs homologue with a 1,2-diacetyl group (C2) was als o prepared as a “water soluble” glycolipid homologue and characterized by 1H NMR spectroscopy. We envisage that each of these chemosynthetic homologues will provide promising approaches to solve medical and biological problems associated with mycoplasma infectious diseases (MIDs).